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Abstract
Autophagy is an intracellular degradation pathway that functions in protein and organelle turnover in response to
starvation and cellular stress. Autophagy is initiated by the formation of a complex containing Beclin 1 (BECN1) and its
binding partner Phosphoinositide-3-kinase, class 3 (PIK3C3). Recently, BECN1 deficiency was shown to enhance the
pathology of a mouse model of Alzheimer Disease (AD). However, the mechanism by which BECN1 or autophagy mediate
these effects are unknown. Here, we report that the levels of Amyloid precursor protein (APP) and its metabolites can be
reduced through autophagy activation, indicating that they are a substrate for autophagy. Furthermore, we find that
knockdown of Becn1 in cell culture increases the levels of APP and its metabolites. Accumulation of APP and APP C-terminal
fragments (APP-CTF) are accompanied by impaired autophagosomal clearance. Pharmacological inhibition of
autophagosomal-lysosomal degradation causes a comparable accumulation of APP and APP-metabolites in autophago-
somes. Becn1 reduction in cell culture leads to lower levels of its binding partner Pik3c3 and increased presence of
Microtubule-associated protein 1, light chain 3 (LC3). Overexpression of Becn1, on the other hand, reduces cellular APP
levels. In line with these observations, we detected less BECN1 and PIK3C3 but more LC3 protein in brains of AD patients.
We conclude that BECN1 regulates APP processing and turnover. BECN1 is involved in autophagy initiation and
autophagosome clearance. Accordingly, BECN1 deficiency disrupts cellular autophagy and autophagosomal-lysosomal
degradation and alters APP metabolism. Together, our findings suggest that autophagy and the BECN1-PIK3C3 complex
regulate APP processing and play an important role in AD pathology.
Citation: Jaeger PA, Pickford F, Sun C-H, Lucin KM, Masliah E, et al. (2010) Regulation of Amyloid Precursor Protein Processing by the Beclin 1 Complex. PLoS
ONE 5(6): e11102. doi:10.1371/journal.pone.0011102
Editor: Charleen T. Chu, University of Pittsburgh, United States of America
Received December 15, 2009; Accepted May 13, 2010; Published June 15, 2010
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public
domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: This work was supported by Biogen IDEC (TWC), the National Institutes of Health (NIH) (TWC: AG030144, EM: AG5131, AG18440, AG22074, AG10435,
and AG02270), The John Douglas French Alzheimer’s Foundation (TWC, FP), and the Veterans Administration Geriatric Research, Education, and Clinical Center
(GRECC) (TWC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors received partial funding from Biogen Idec. However, no competing interests exist, and all data and materials are available to
the scientific community in adherence to all the PLoS ONE policies.
* E-mail: twc@stanford.edu
¤ Current address: Merck Research Laboratories, Boston, Massachusetts, United States of America
Introduction
Alzheimer Disease (AD) affects a growing number of the elderly
and results in dramatic loss of cognitive function. It is
characterized pathologically by the presence of extracellular beta
amyloid (Ab) assemblies called plaques [1,2], and intracellular
accumulation of Ab [3] and tau [4]. These lesions are hallmarks of
the disease and are associated with neurodegeneration and
inflammation [5]. Currently it is unclear how these lesions form,
and how protein aggregation and neuronal loss are connected [6].
While much research has centered on abnormal proteolytic
processing of Amyloid precursor protein (APP) and tau, less focus
has been placed on the possibility that slow, progressive
dysfunction of intracellular protein sorting and degradation
pathways, such as macroautophagy, may drive pathogenesis
steadily over time, especially in cases of sporadic AD [7,8].
APP is a type I transmembrane protein that can be processed by
one of two mutually exclusive cleavage pathways: a-secretase (non-
amyloidogenic processing) or b-secretase (amyloidogenic process-
ing) followed by c-secretase cleavage. Non-amyloidogenic cleavage
occurs mainly at the cell surface, whereas amyloidogenic
processing takes place in intracellular compartments, including
endosomes, lysosomes, and autophagosomes [9,10]. Amyloido-
genic processing releases Ab which can subsequently be secreted
from cells. In addition, APP C-terminal fragments (APP-CTF) of
both cleavage pathways can translocate to the nucleus and induce
nuclear signaling [11,12,13,14]. Both, Ab and APP-CTF poten-
tially contribute to AD pathology and can exhibit neurotoxic
properties through multiple pathways [15,16].
APP levels, Ab levels, and neurodegeneration are tightly coupled.
Less than 1% of all AD cases are autosomal dominant early-onset
familial AD (FAD) and are caused by mutations in one of three
major genes APP, Presenilin-1 (PSEN1), or Presenilin-2 (PSEN2)
[17]. These mutations lead to the predominant amyloidogenic
cleavage of APP. Additionally, FAD can be caused by APP locus
duplication [18] and polymorphisms in the APP promoter region
that increase APP levels have been linked to an increased risk for
AD [19]. In Down Syndrome an additional copy of chromosome
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protein,elevatedAblevels,plaquedepositionandAD-likediseasein
all older Down’s patients [20,21,22]. While this illustrates the
importance of APP gene regulation and APP protein levels in AD,
little is known about the regulation of APP metabolism in sporadic
AD cases. The levels of APP protein and APP mRNA in AD cases
versus control has been reported in the past with conflicting results,
butmorerecentresearchindicatesincreasedlevelsofAPPand APP-
CTFs in sporadic AD brains [23,24,25,26].
Macroautophagy (in this paper referred to as ‘autophagy’) is a
major pathway involved in the degradation of long-lived proteins,
protein aggregates, and organelles, cellular remodeling, and
survival during starvation [27,28]. Autophagy is characterized by
the formation of a cup-shaped isolation membrane that develops
around cytosolic components and eventually fuses to form a
double membrane bound vesicle [29,30,31,32]. The protein
Microtubule-associated protein 1, light chain 3 (LC3) is anchored
via conjugated phosphatidylethanolamine to the vesicle’s mem-
brane. While the un-conjugated LC3 is called LC3-I, the
phosphatidylethanolamine conjugated LC3 is referred to as
LC3-II and is a specific marker for these so-called autophagosomes
[33]. Autophagosomes then undergo several microtubule- [34]
and dynein-dependent maturation events [35,36], including
fusions with multivesicular bodies, early and/or late endosomes
[37], before eventually fusing with lysosomes [38,39].
Autophagy has recently been implicated in a number of diseases
including neurodegenerative conditions and it appears that autoph-
agy can exert both a pathological or protective role, depending on the
setting [40]. While it is still largely unknown how dysfunction of the
autophagy pathway might contribute to neurodegeneration and AD,
recent papers suggest a role for Beclin 1 (BECN1) in AD and mild
cognitive impairment [41,42,43]. Haploinsufficiency of Becn1 in mice
decreases neuronal autophagy and promotes neuronal degeneration
[41]. Moreover, in a mouse model for AD genetic reduction of Becn1
expression results in increased accumulation of APP fragments and
Ab, increased neurodegeneration and increased inflammation [41].
In addition, Autophagy has been shown to protect neurons from Ab
induced cytotoxicity [44,45,46].
BECN1 plays an important role in autophagy [47,48,49,50,51] and
is the human homolog of the yeast autophagy protein Atg6/Apg6 [52].
BECN1 forms a core complex with the class 3 phosphoinositide-3-
kinase PIK3C3 (also known as Vps34) [51,53,54]. Other proteins such
as UVRAG, Atg14L, PIK3R4/Vps15, Ambra1, Rubicon, or Bif-1,
join this complex depending on its physiological function in autophagy
or endosomal trafficking [55,56,57]. Becn1 and Pik3c3 mRNA and
protein are expressed in human and mouse brains [40] (Fig. S1, from
the Allen Mouse Brain Atlas. Seattle (WA): Allen Institute for Brain
Science. Available from: http://mouse.brain-map.org [58]). Knockout
mice lacking Becn1 (Becn1
2/2) die during embryogenesis [48,50].
To date, the mechanism describing how deficiency in BECN1
cancausechangesinAPPprocessing and amyloid accumulationare
unknown. Here we characterize the relationship between BECN1
levels, autophagy, and APP processing in cell culture and in human
brain tissue. We show that intracellular APP, APP-CTFs, and Ab
can be reduced by autophagy activation and that the BECN1-
PIK3C3 complex regulates APP processing and accumulation.
Results
Activation of autophagy promotes APP, APP-CTF, and Ab
degradation
Activation of autophagy can lead to degradation of a-synuclein,
huntingtin, and poly-ubiquitinated proteins [59,60,61,62]. To test
whether APP and APP-CTFs can also be reduced through this
mechanism, we induced autophagy in B103 rat neuroblastoma
cells which lack endogenous rat APP and are stably transfected
with wildtype human APP695 (B103/hAPP) [63]. To induce
autophagy we used either starvation [64] or rapamycin treatment
which inhibits mTOR and activates autophagy [65] (Fig. 1A). APP
and APP-CTF levels were significantly reduced in starved B103/
hAPP cells and further reduced in rapamycin treated B103/hAPP
cells (Figure 1B–C). Rapamycin treatment did not affect APP
mRNA levels analyzed by qRT-PCR (data not shown). Further-
more, inhibition of autophagy through lenti-viral Atg5 siRNA
significantly impaired starvation-induced autophagosomal clear-
ance of APP (Fig. S2). Similar to the findings in neuronal cells,
Chinese hamster ovary (CHO) cells stably transfected with human
APP695 (CHO/hAPP) [12] and treated with the autophagy
inducer thapsigargin [66] showed a more than 50% reduction in
APP and APP-CTF levels (Fig. 1D–F) and significantly reduced
levels of Ab in the cell supernatant (Fig. 1G). Consistent with these
biochemical findings, microscopy (Fig. 1H) revealed reductions
both in intracellular APP (detected with CT20 antibody) and in
cell surface APP (detected on non-permeabilized cells with 8E5
antibody). These findings indicate that autophagy activation can
reduce levels of APP and APP metabolites.
Becn1 knockdown increases APP, APP-like proteins, APP-
CTFs and Ab
The reported reduction in BECN1 in AD brains [41,42] and the
increased plaque formation and neurodegeneration in Becn1
+/2APP
mice [41] led us to investigate whether Becn1 deficiency affected
APP production, processing, or degradation in vitro. Reduction of
Becn1bysiRNA inB103/hAPPcells more than doubled the levelsof
cellular APP and APP-CTFs (Fig. 2A and S3). Moreover, the
reduced levels of Becn1 also increased the amount of secreted Ab in
the cell culture supernatant when compared to cells treated with a
scrambled control siRNA (Fig. 2B). Similar results were obtained
with two different siRNA sequences (data not shown). CHO/hAPP
cells treatedwith Becn1 siRNAalsoshowed twofold increasesinAPP
and APP-CTFs (Fig. 2 C and D). This prominent increase in APP
protein in Becn1 siRNA treated cells could also be visualized and
quantified with fluorescent microscopy showing increased immu-
noreactivity for both, C-terminal (CT20) and N-terminal (8E5) APP
antibody stains (Fig. S4).
Reduced autophagic activity could be specific for APP degrada-
tion or it could also affect the processing of amyloid precursor-like
proteins. Both, Amyloid precursor like protein-1 (APLP1) and
Amyloid precursor like protein-2 (APLP2) are substrates of a-, c-,
and e-secretase cleavage in a similar manner as APP, while APLP2
can also be cleaved by b-secretase [67]. APP, APLP1, and APLP2
can form homo- and heterodimers [68], making it possible that they
are affected similarly by processing alterations. To test if autophagy
plays a role in APLP1 and APLP2 degradation, we applied Becn1
siRNA to cell lines stably expressing human APLP1 or APLP2 [12].
Reducing Becn1 in CHO/hAPLP1 and CHO/hAPLP2 cells
resulted in significant increases in APLP1 (Fig. 2E–F) and APLP2
levels, respectively (Fig. 2G–H).
To exclude the possibility that the observed cellular changes in
APP, APP-CTF, and Ab levels in response to Becn1 siRNA could
be accounted for by transcriptional up-regulation of APP mRNA
levels, we performed qRT-PCR on Becn1 or control siRNA treated
B103/hAPP cells. APP mRNA levels decreased slightly in Becn1
siRNA treated B103/APP cells (Fig. 2J), therefore increases in
APP, APP-CTFs, and Ab cannot be attributed to increased
transcription of the precursor.
To reduce potential transfection related effects, we transduced
CHO/hAPP cells with a lentivirus (LV) containing either a control
Beclin 1 and APP Metabolism
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a Becn1 shRNA sequence (Becn1 shLV; different sequence from the
siRNA’s used above). The Becn1 shRNA LV treated cells exhibited
a significant increase in APP immunofluorescence when compared
to GFP LV treated control cells (Fig. 2K–L).
In the Becn1 siRNA treated cells there was a significant
correlation between Ab and APP, and between Ab and APP-
CTFs (R=0.619, p=0.03 and R=0.698, p=0.01, respectively,
data not shown), suggesting that the increase in secreted Ab was
due to increased levels of its precursor, APP. The Ab/APP ratio
was similar in control and Becn1 siRNA treated B103/APP cells
(data not shown), suggesting unchanged c-secretase activity. To
further test the role of c-secretase in the observed effects, we
treated control or Becn1 shLV transduced B103/hAPP cells with
DAPT, a c-secretase inhibitor. This treatment had no significant
effect on the accumulation of full-length APP in control cells
(Fig. 2M and S5) and did not significantly enhance the levels of
full-length APP in Becn1 shLV treated cells any further. The APP-
CTF levels on the other hand were significantly increased after
DAPT treatment (indicating successful c-secretase inhibition) and
this effect was additive when DAPT was applied together with
Becn1 shLV. These results indicate that the accumulation of APP
and APP-CTFs in the Becn1 deficient cells are unlikely the result
of substantial changes in c-secretase activity.
In summary, these findings show that reduced Becn1 levels can
cause intracellular accumulation of APP and its metabolites and
increased secretion of Ab. This accumulation appears not to be
restricted to APP but also affects other APP-family members,
suggesting that the observed accumulations are due to changes in
shared processing and trafficking pathways. Finally, the buildup of
APP and APP-CTFs mediated by Becn1 deficiency appears to be
independent of c-secretase activity.
Overexpression of APP does not change Becn1 or Pik3c3
protein levels
Brains from AD patients contain less BECN1 protein and
mRNA than non-demented controls [41,42,43]. This reduction
Figure 1. Activation of autophagy promotes APP, APP-CTF, and Ab degradation. A–C. B103/hAPP cells were left untreated (Ctrl), starved
for 90 min in HANKS solution (Starv), or treated with 100 nM rapamycin in DMEM (Rap) for 90 min. Western blots (A) and quantification (B, C) of RIPA
cell lysates probed with the CT15 antibody recognizing full-length APP and APP-CTFs and with an actin antibody as a control for loading. D–F. CHO/
hAPP cells were left untreated (Ctrl) or treated for 12 hrs with 3 mM thapsigargin (Thaps) in DMEM/10%FBS. Western blots (D) and quantification (E, F)
of RIPA cell lysates probed with antibodies as in A. (Data from the same blot. The vertical line indicates removal of three lanes not part of this
experiment.) G. Secretion of Ab into the cell supernatant was measured by ELISA (12 hrs/1 mM Thaps) H. Epifluorescence microscopy images of CHO/
hAPP cells treated as in D, permeabilized with Tween and stained with antibody CT20 to label all cellular APP, or not permeabilized and stained with
antibody 8E5 which recognizes the ectodomain of APP at the cell surface (scale bar represents 25 mm). Bars are mean 6 SEM from triplicate cultures
of at least two independent experiments. * p,0.05, ** p,0.01, *** p,0.001 by unpaired Student’s t test.
doi:10.1371/journal.pone.0011102.g001
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increase in APP levels. To measure the effects of APP expression
on Becn1 and Pik3c3 levels, we compared B103 cells that were
stably transfected with a mock vector and express no endogenous
APP (B103/mock) with cells that were stably transfected with
human APP (B103/hAPP; these cells express close to endogenous
levels of APP [69]) (Fig. 3A). While APP and APP-CTF levels were
strongly increased, Becn1 and Pik3c3 levels were unchanged in
B103/hAPP cell compared to B103/mock cells (Fig. 3B).
Expression levels of APP that are chronically much higher than
normal could have an effect on Becn1 and Pik3c3 levels. To
measure the effects of higher than endogenous levels of APP
expression on Becn1 and Pik3c3 levels, we compared CHO cells
that were stably transfected with a mock vector and express only
endogenous hamster APP (CHO/mock) with cells that were stably
transfected with a hAPP vector and express high hAPP levels
(CHO/hAPP) (Fig. 3C). Becn1 and Pik3c3 levels remained
unchanged despite a strong elevation in APP and APP-CTF levels
in these cells (Fig. 3D). These findings indicate that the levels of
cellular APP or APP-CTF do not directly influence Becn1 and
Pik3c3 levels.
Reduction of Becn1 impairs degradation of
autophagosomes and reduces Pik3c3 levels
To investigate how the observed effects of Becn1 reduction on
APP-family protein processing can be linked to autophagy, we
measured the levels of the autophagosomal marker LC3-II in
Becn1 siRNA treated CHO/hAPP, CHO/hAPLP1, and CHO/
hAPLP2 cells (Fig. 4A and data not shown). A 75% knockdown of
Becn1 (Fig. 4B) caused a significant shift in the LC3-II/LC3-I ratio
indicating an accumulation of autophagosomes in all three cell
lines (Fig. 4C and data not shown).
Becn1 is a core component of the class 3 PI3 kinase complex
[70]. Reduction of Becn1 levels could affect the stability of this
complex and influence the levels of other proteins in the complex.
To address this possibility we measured the levels of Pik3c3 in
response to Becn1 siRNA treatment, and the levels of Becn1 in
response to Pik3c3 siRNA (Fig. 4D). The cellular levels of both
proteins, Becn1 and Pik3c3, appear to be linked, with the
reduction of one leading to a comparable reduction of the other
(Fig. 4E).
These findings led us to investigate if Pik3c3 reduction by itself
can cause a change in APP processing, similar to Becn1 siRNA
Figure 2. Becn1 knockdown increases APP, APP-like proteins, APP-CTFs and Ab. A–B. B103/hAPP cells were treated with Becn1 siRNA for
48–72 hrs. Cells were left untreated (U), treated with transfection reagent alone (no RNA), treated with scrambled siRNA (Ctrl siRNA [C]), or treated
with Becn1 siRNA (Becn1 siRNA [B]). Western blots (A) of RIPA cell lysates were probed with a Becn1 antibody, the CT15 APP antibody, and with an
actin antibody as a control for loading. For quantification see Fig, S2. (Data from two blots with identical exposure times. Blot border indicated by
vertical black line.) Total Ab1-x concentrations measured by ELISA in cell culture supernatant from the same cells at 72 hrs (B). C–D. CHO/hAPP cells
were treated with Becn1 siRNA for 48 hrs. Western blots (C) and quantification (D) of RIPA cell lysates that were probed with a Becn1 antibody, the
CT15 APP antibody, and with an actin antibody as a control for loading. E–F. CHO/APLP1 cells were treated with Becn1 siRNA for 48 hrs. Western
blots (E) and quantification (F) of RIPA cell lysates that were probed with a Becn1 antibody, an APLP1 antibody, and with an actin antibody as a
control for loading. G–H. CHO/APLP2 cells were treated with Becn1 siRNA for 48 hrs. Western blots (G) and quantification (H) of RIPA cell lysates that
were probed with a Becn1 antibody, an APLP2 antibody, and with an actin antibody as a control for loading. J. Levels of APP mRNA were compared
by qRT-PCR in scrambled [C] or Becn1 [B] siRNA treated B103/hAPP cells. K–L. CHO/hAPP cells were treated with either GFP lentivirus or Becn1 shRNA-
GFP lentivirus. Quantification of the relative APP immunofluorescence (K) and epifluorescence microscopy (L) of GFP lentivirus or Becn1 shRNA-GFP
lentivirus treated permeabilized CHO/hAPP cells, probed with DAPI and CT20 APP antibody (scale bar represents 10 mm). M. Inhibition of c-secretase
activity through 100 nM DAPT treatment had no significant effect on APP levels and an additive effect on APP-CTF accumulation with Becn1 shLV
treatment. Bars are mean 6 SEM from duplicate/triplicate cultures of at least two independent experiments. * p,0.05, ** p,0.01, *** p,0.001 by
unpaired Student’s t test.
doi:10.1371/journal.pone.0011102.g002
Beclin 1 and APP Metabolism
PLoS ONE | www.plosone.org 4 June 2010 | Volume 5 | Issue 6 | e11102(Fig. 4A). While we observed a trend towards increased APP-CTF
in Pik3c3 siRNA treated cells, we found no significant differences
(Fig. 4F–G). These data support a central role for Becn1 in
modulating APP levels.
Inhibition of autophagosome turnover leads to a
reduction in Becn1 and Pik3c3 levels
BECN1 is reduced in AD brains [41,42,43], however the
mechanism behind this reduction is unknown. One hypothesis is
that impaired autophagosomal-lysosomal function may activate a
negative feedback loop that subsequently reduces BECN1 levels. It
is conceivable that this homeostatic loop could become activated
after autophagy is impaired in order to prevent apoptosis or
autophagic cell death [71]. An accumulation of autophagosomes
in AD brain tissue (indicating impaired autophagosomal degrada-
tion) has been reported previously [7,10,72,73]. To test this
hypothesis we inhibited autophagosomal-lysosomal fusion using
bafilomycin A1 (BafA) [74,75]. BafA treatment has been shown to
lead to accumulation of APP and APP-CTFs in late endosomes
and multivesicular bodies (MVB) [76]. We tested if BafA treatment
can also lead to APP and APP-CTF accumulation in autophago-
somes and if the accumulation of these autophagosomes has any
effects on Becn1 or Pik3c3 levels.
In B103/hAPP cells BafA treatment led to a strong increase in
APP and APP-CTFs compared to vehicle treated cells (Fig. 5A–C).
It also led to a significant accumulation of LC3-I and LC3-II
(Fig. 5A), indicating a successful inhibition of autophagosomal
degradation through BafA treatment. This impairment of
autophagy caused a significant decrease in Becn1 (Fig. 5D,
p=0.025) and reduced, but not significantly changed, Pik3c3
levels (Fig. 5E, p=0.063). Microscopy revealed that APP
accumulates primarily in large vacuoles in the perinuclear space
(Fig. 5F). Some APP containing vesicles stained positive for LC3
(Fig. 5F, arrowheads) but APP also accumulated in large non-LC3
positive vesicles (Fig. 5F, arrow). In vehicle treated cells only very
little APP was found in LC3 positive compartments and these
compartments were small in size (Fig. 5F).
Similar results were obtained for CHO/hAPP cells, where
treatment with BafA also led to a reduction in Becn1 and Pik3c3
protein levels respectively (Fig. 5G, 5K–L). While CT20 full length
APP immunoreactivity slightly decreased (Fig. 5H), a strong
increase in APP-CTFs (Fig. 5J) and in sAPP (Fig. 5M–N) were
observed. The reduction of full-length APP in CHO/hAPP cells
(Fig. 5G–H) can be attributed to elevated intracellular and
extracellular cleavage of APP. The antibody used in Fig. 5G
(CT20) does not recognize the N-terminal cleavage product
(Fig. 5P) and enhanced APP processing will lead to an apparent
reduction in intracellular (full-length) APP (CT20) levels. Accord-
ingly, the N-terminal sAPP cleavage product accumulates both in
the cell supernatant (Fig. 5M–N) and in intracellular, Lyso-
Tracker-positive vesicles (Fig. 5O) when probed with the N-
terminal antibody 8E5. Total APP and its metabolites accumulate
in CHO/hAPP cells, consistent with a disruption in autophago-
somal degradation.
To explore alternative inhibitors of autophagosomal-lysosomal
degradation and rule out unspecific BafA effects, we compared
control, BafA, chloroquine (CQ), and ammonium-chloride/
leupeptin (NL) treated CHO/hAPP and B103/hAPP cells (Fig.
Figure 3. Overexpression of APP does not change Becn1 or Pik3c3 protein levels. A–B. B103 cells were stably transfected with an empty
plasmid (mock) or a hAPP encoding plasmid. Western blots (A) and quantification (B) of RIPA cell lysates that were probed with the CT15 APP, a
Becn1, and a Pik3c3 antibody. An actin antibody was used as a loading control. C–D. CHO cells were stably transfected with an empty plasmid (mock)
or a hAPP encoding plasmid. Western blots (C) and quantification (D) of RIPA cell lysates that were probed with the CT15 APP, a Becn1, and a Pik3c3
antibody. Actin antibody was used as a loading control. Bars are mean 6 SEM from triplicate cultures of at least two independent experiments. *
p,0.05, ** p,0.01, *** p,0.001 by unpaired Student’s t test.
doi:10.1371/journal.pone.0011102.g003
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APP and APP-CTFs, very similar to BafA. This strongly supports
the hypothesis that APP is indeed processed through the
autophagosomal-lysosomal pathway. Interestingly, we observe
the highest reduction in Becn1 and Pik3c3 levels after BafA
treatment. CQ treatment causes a slight (p=0.06) reduction in
Becn1 and a significant reduction in Pik3c3, while NL has no
significant effect on Becn1 or Pik3c3. BafA inhibits autophagoso-
mal-lysosomal fusion, while the two other treatments primarily
inhibit autolysosomal degradation. This supports the hypothesis
that the accumulation of autophagosomes, rather then the
inhibition of lysosomal degradation, affects Becn1 and Pik3c3
levels in a negative feedback-loop.
We conclude that inhibition of autophagosomal-lysosomal
fusion through pharmacological treatments leads to accumulation
of APP, APP-CTF, sAPP, and autophagosomes. This accumula-
tion results in a reduction of Becn1 and Pik3c3 levels, possibly
through a negative feedback mechanism.
Becn1 overexpression reduces APP immunoreactivity
To determine if Becn1 overexpression alone can reduce APP
baseline levels we transduced CHO/hAPP cells with either a Becn1
LV or a control GFP LV (Fig. 6A). While baseline Becn1 levels
give only very faint immunoreactivity in fluorescent microscopy,
the Becn1 LV treated cells exhibited a wide range of Becn1
expression levels (from baseline to strong overexpression, Fig. 6A).
We randomly selected N=214 Becn1 LV treated cells covering the
whole spectrum of Becn1 expression from both, the Becn1 (red
outline) and APP channel (yellow outline), and measured their
relative Becn1 and APP immunofluorescence (Fig. 6B). Next, we
grouped these cells into low (,20th percentile), medium (20–80th
percentile), and high (.80th percentile) Becn1 expressing cells and
compared the median APP immunofluorescence in these groups
(Fig. 6C). While no or low overexpression of Becn1 has no effect
on APP immunoreactivity (Fig. 6C, 0–20), medium overexpression
significantly reduces baseline APP levels (Fig. 6C, 20–80). Very
strong, and likely non-physiological overexpression of Becn1
(Fig. 6C, 80–100) had no lowering effect on APP immunoreac-
tivity, but led to either abnormally decreased or increased cell size,
indicating that these very high levels of Becn1 expression might
impair cellular homeostasis (Fig. S7A–B). This last finding is
similar to very high overexpression of GFP protein and probably
an artifact. For more details on the effects of GFP overexpression
in the control cells, see supplemental Fig. S7 B. These results
Figure 4. Reduction of Becn1 impairs degradation of autophagosomes and reduces Pik3c3 levels. A–C. CHO/hAPP cells were treated
with Becn1 siRNA for 48 h. Western blots (A) of RIPA cell lysates were probed with a Becn1 and LC3 antibody. An actin antibody was used as a loading
control. Quantification (B) of the Becn1 band intensity and the ratio of LC3-II to LC3-I (C). D–E. CHO/hAPP cells were treated with Becn1 and Pik3c3
siRNA for 48 h. Western blots (D) and quantification (E) of RIPA cell lysates that were probed with a Becn1 and Pik3c3 antibody. An actin antibody was
used as a loading control. F–G. CHO/hAPP cells were treated with Pik3c3 siRNA for 48 h. Western blots (F) and quantification (G) of RIPA cell lysates
that were probed with the CT15 APP antibody and with an actin antibody as a control for loading. Bars are mean 6 SEM from triplicate cultures of at
least two independent experiments. * p,0.05, ** p,0.01, *** p,0.001 by unpaired Student’s t test.
doi:10.1371/journal.pone.0011102.g004
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APP-lowering effect in CHO/hAPP cells, as long as Becn1 is not
expressed at extremely high and probably non-physiological levels.
AD brains have less BECN1 and PIK3C3 and more LC3
BECN1 and PIK3C3 form a complex with PI3 kinase (PI3K)
activity that is necessary for the classical autophagy-activating
pathway through mTOR. We and others have previously shown
that BECN1 is strongly and specifically reduced in affected regions
of Alzheimer’s disease (AD) brains [41,42,43]. Heterozygous
deletion of Becn1 in an AD mouse model caused increased
neurodegeneration, decreased autophagy, and disruption of the
lysosomal system [41]. Our cell culture findings presented above
indicate that BECN1 plays an important role in APP processing
and trafficking and that BECN1 reduction has effects on the PI3K
complex stability and autophagosomal degradation. To under-
stand if the observed reduction of BECN1 in AD patients is an
isolated finding or if it could causes a more general disturbance of
the autophagosomal system (similar to our in vitro findings) we
measured multiple key proteins involved in autophagy (Fig. 7A) in
human brain samples. Protein was extracted from cortical gray
matter of confirmed Alzheimer disease patients (N=7, age
81612.6 years, MMSE 4.366.1) and non-demented control
subjects (N=10, age 77.768.1 years, MMSE 28.363.0), using a
detergent containing extraction buffer (RIPA). We found PIK3C3
and, consistent with our previously published findings [41],
BECN1 to be strongly reduced in AD brains when compared to
non-demented age-matched controls (Fig. 7B–C). There was a
highly significant correlation between the amount of BECN1 and
PIK3C3 (Fig. 7D, R=0.86, p,0.0001) in agreement with their
Figure 5. Inhibition of autophagosomal turnover leads to a reduction in Becn1 and Pik3c3 levels. A–E. B103/hAPP cells were treated
with vehicle (DMSO) or 50 nM BafA for 24 hrs to inhibit autophagosomal degradation. Western blots (A) and quantification (B–E) of RIPA cell lysates
that were probed with CT15 APP, LC3, Becn1, and Pik3c3 antibody. An actin antibody was used as a loading control. F. Confocal microscopy of B103/
hAPP cells treated with vehicle (DMSO) or 100 nM BafA for 24 hrs. Cells were stained with CT20 APP antibody (magenta) and LC3 antibody (cyan). Co-
localization is indicated in yellow. Arrowheads indicate LC3 positive APP containing vesicles. The arrow indicates an APP containing LC3 negative
vesicle (scale bar represents 10 mm). The line indicates cross-section. Cyan line in the cross-section represents APP intensity, magenta line represents
LC3 intensity (AU). G–L. CHO/hAPP cells were treated with vehicle (DMSO), 50 nM, or 100 nM BafA (WB data not shown) for 24 hrs. Western blots (G)
and quantification (H–L) of RIPA cell lysates that were probed with the CT15 APP, LC3, Becn1, and Pik3c3 antibody. An actin antibody was used as a
loading control. M–N. BafA and CQ treatment cause increased APP processing which in turn leads to elevated levels of secreted APP (sAPP) in the cell
supernatant (M). This is quantified in (N). O. Epifluorescence microscopy of CHO/hAPP cells treated with vehicle (DMSO) or 100 nM BafA for 12 hrs.
Cells were stained with the 8E5 APP antibody (magenta) and LysoTracker (cyan). Co-localization is indicated in yellow (scale bar represents 25 mm).
P. Schematic representation of the APP antibody epitopes. Bars are mean 6 SEM from triplicate cultures of at least two independent experiments.
*p ,0.05, ** p,0.01, *** p,0.001 by unpaired Student’s t test.
doi:10.1371/journal.pone.0011102.g005
Figure 6. Becn1 overexpression reduces APP immunoreactivity. A. CHO/hAPP cells were transduced with either a GFP LV (GFP control) or a
mBecn1 LV (Becn1 o.e.). Epifluorescence microscopy was performed after staining with Becn1 and APP CT15 antibodies (Scale bar represents 25 mm).
GFP LV transduced cells show very faint Becn1 immunoreactivity, while Becn1 LV transduced cells exhibit a range of Becn1 signal intensity. No GFP
signal is present in the Becn1 LV cells. A random selection of cells (N=214) was picked from the GFP LV cells and the Becn1 LV cells. The Becn1 LV cells
were randomly selected in both, the APP (yellow outline) and the Becn1 (red outline) channel. B. Relative immunofluorescence of the selected cells
(AU). They can be divided in low, medium, and high Becn1 expressing cells. C. Quantification of the relative APP immunofluorescence in the three
cohorts. Medium Becn1 overexpression leads to a significant reduction in APP levels. Medians were compared by Man-Whitney U test. * p,0.05,
** p,0.01, *** p,0.001
doi:10.1371/journal.pone.0011102.g006
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In support of previous findings by others [10], we measured
elevated levels of LC3-I and LC3-II in AD patient brains (Fig. 7E)
and we observed a trend towards higher LC3-II/LC3-I ratios
(Fig. 7F). In contrast, expression levels of another autophagy
protein, ATG5 were unchanged in AD brains, indicating that only
portions of the autophagy pathway are de-regulated in AD
(Fig. 7A&E). To ensure that the observed reduction in BECN1
and PIK3C3 levels cannot be attributed to a gross decrease in
neuronal mass, we measured the levels of the marker neuron-
specific enolase (NSE) in lysates from AD and non-demented
control brains and found no significant difference (Fig. 7G–H).
Tissue protein measurements are very sensitive to the extraction
method used. To rule out extraction artifacts, we extracted a
different set of human gray matter tissue (AD N=10, age
77.967.7 years, MMSE 4.965.4/Ctrl N=10, age 77.068.2
years, MMSE 29.361.0) with sequential extraction buffers
yielding a cytosolic fraction (RAB buffer) and a membrane bound
fraction (RIPA buffer). BECN1, PIK3C3, and ATG5 were
predominantly found in the membranous protein fraction with
BECN1 and PIK3C3 again significantly reduced in AD brain
tissue and ATG5 levels unchanged (Table S1, p=0.003 and
p=0.019).
Discussion
Recent advances in our understanding of intracellular protein
trafficking have shown that subtle alterations in the intracellular
distribution of APP can have strong effects on whether it is
processed by the non-amyloidogenic or amyloidogenic pathways
Figure 7. AD brains have less BECN1 and PIK3C3 and more LC3. A–H. Comparison of protein levels in frontal cortex (gray matter) from AD
brains and age matched, non-demented, non-pathological controls. Western blots (A) and quantification (B–F) of RIPA lysates that were probed with
the CT20 APP, LC3, Becn1, Pik3c3, and Atg5 antibody. An actin antibody was used as a loading control. 7 AD and 10 control cases were used. BECN1
and PIK3C3 levels were significantly reduced in AD cases (B–C). A significant linear correlation exists between BECN1 and PIK3C3 levels (R=0.86,
p,0.0001), consistent with them functioning in a complex (D). While ATG5 levels appear unchanged, LC3-I and LC3-II levels are significantly elevated
(E). A slight trend was detected in LC3-II/LC3-I ratio change (F). No significant difference could be detected in the levels of a neuronal marker NSE
between the control and AD brains, indicating that the observed changes are not due to gross neuronal loss (G and H). All scattergrams show mean
6 SEM. Means were compared by unpaired Student’s t test. * p,0.05, ** p,0.01, *** p,0.001
doi:10.1371/journal.pone.0011102.g007
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is a degradative pathway that has the capacity to reduce cellular
levels of APP and its metabolites when activated either
physiologically (starvation), through pharmacological treatment
(rapamycin or thapsigargin), or by lentiviral overproduction of
Becn1. Conversely, reduced expression of Becn1 or pharmaco-
logical inhibition of autophagosomal degradation (bafilomycin A1,
chloroquine, ammonium-chloride/leupeptin) led to an increase in
APP and its metabolites. We conclude that Becn1 is a key
regulator of cellular APP turnover.
Autophagy is a physiological mechanism that can have both
beneficial and detrimental effects on neurons, depending on the
circumstances [40]. Whether or not autophagy is increased in AD
and whether such an increase reflects a protective attempt by cells
to possibly degrade APP and Ab, or a neurotoxic process
promoting autophagic cell death has been debated. However,
recent publications indicate that pharmacological stimulation of
autophagy can be beneficial and reduce Ab mediated toxicity
[44,45,46]. In human brains and AD mouse models autophago-
somes can be readily detected by electron microscopy and they
appear to accumulate in swollen dystrophic neurites [7,10,72,73].
This is most commonly interpreted as a sign of impaired
autophagosomal degradation [7]. Furthermore APP-cleaving
secretases and Ab have been localized to autophagosomes and
the accumulation of autophagosomes in AD brains and APP/PS1
mice has been interpreted as evidence that autophagy could
promote AD pathology [10]. In agreement with these neuropath-
ological findings, we observed that APP transgenic mice
accumulate lysosomal and autophagosomal vesicles and that
Becn1 deficiency in APP mice further promotes this pathology
[41]. In addition, we confirm here that autophagy is activated in
AD by detecting increased levels of LC3-II in AD brains (Fig. 7E).
However, at the same time, we and others found BECN1
[41,42,43] and in the current study PIK3C3, reduced in AD tissue
(Fig. 7B–C and Table S1), suggesting an impairment in the
initiation of autophagy. To reconcile these apparently contradic-
tory findings we postulate a dual role for BECN1: one in
autophagy initiation, in a complex with PIK3C3, and another in
autophagosomal flux and degradation, potentially in a complex
with other proteins (Fig. 8). BECN1 has been shown to execute
various functions depending on its binding partners and siRNA
mediated knockdown of Becn1 has been demonstrated to impair
autophagosomal degradation and cause LC3-II accumulation at
the same time [57], similar to our findings (Fig. 4A&C). Different
experimental models therefore appear to reflect different aspects of
this dual role. On one hand Becn1 heterozygous knockout mice
have reduced autophagosomes and reduced LC3-II [41], reflect-
ing impaired autophagosomal initiation. On the other hand, Becn1
siRNA treated CHO cells have increased LC3-II levels
(Fig. 4A&C). This reflects impaired autophagosomal degradation
similar to the pathology observed in AD brains. In either role,
reducing BECN1 leads to pathological accumulations of APP and
its metabolites through impaired autophagy (Fig. 8).
Our observations regarding the effect of Becn1 siRNA on
autophagy confirm that the BECN1-PI3K complex has a crucial
role during the initiation stages of autophagy, but they also show
that reduction of Becn1 protein levels can have effects on the
availability of PIK3C3 and vice versa (Fig. 4D–G). This is
supported by recent findings of similar Becn1 reduction after
Pik3c3 knockdown [78], although a reduction of Pik3c3 after Becn1
Figure 8. Effects of BECN1 deficiency in AD. In healthy individuals, APP is transcribed in the endoplasmatic reticulum (ER, grey), modified in the
golgi network (Golgi, grey) and then shuttled to the cell surface through the secretory pathway (SecP, grey). The cell takes up APP through
endocytosis (End, light blue). From here, APP can either be degraded via autophagy (Aut, yellow) and the lysosomes (Lys, dark blue) or APP can be
recycled via the recycling endosomes (R-End, light blue) and enter the cycle again. In AD brains and Becn1 deficient cells BECN1 deficiency impairs
both induction of autophagy (through the complex with PIK3C3) and autophagosomal degradation (potentially through a complex with an unknown
binding partner). APP containing vesicles (endosomes, autophagosomes, and others) build up inside the cell. APP is increasingly cleaved by
secretases and large amounts of APP-CTF and Ab are being released, causing neurotoxic events. The disruption of autophagosomal degradation
includes an increasing accumulation of autophagosomes. This accumulation can further inhibit autophagy and BECN1 expression (red arrow),
worsening the reduction in APP turnover and degradation.
doi:10.1371/journal.pone.0011102.g008
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determine if other proteins that are part of the BECN1 complex
(Atg14L, PIK3R4, UVRAG, Ambra1, Vps15, Bif-1, or Rubicon)
are also reduced in AD or in response to BECN1 reduction,
respectively, as this could help explain the (possibly indirect) effects
of BECN1 reduction on autophagosomal degradation (Fig. 8).
Atg14L and UVRAG are especially interesting candidates for this
since both proteins have been shown to determine the stability of
Becn1 [78] and Atg14L knockdown causes LC3-II accumulation
similar to Becn1 siRNA [57]. Further studies will be needed to
precisely determine the role of Becn1 and its binding partners in
the modulation of autophagic flux and autophagosomal matura-
tion. Nevertheless, with respect to APP metabolism, Becn1 seems
to play central role, since Pik3c3 siRNA does not cause a
comparable effect on APP accumulation in our in vitro system
(Fig. 4F–G).
Aiming to validate our cell culture findings in AD brain tissue,
we measured the levels of PIK3C3, LC3, and ATG5. We found a
reduction not only of BECN1, but also of its binding partner
PIK3C3, similar to our cell culture model using Becn1 siRNA
(Fig. 7C). Importantly, we observed a linear relationship between
the levels of these two proteins (Fig. 7D) similar to the cell culture
studies, supporting the idea that reduction in one of the proteins
can cause instability of the PI3K complex and increased
degradation or reduced production of the respective binding
partner. The levels of ATG5 on the other hand were not
significantly changed, arguing for a specific disruption of the PI3K
complex in AD rather than a general deficiency in the autophagy
pathway and signaling cascade. The reduction in PI3K complex
components appear to have an inhibiting effect on the degradation
rate of autophagosomes, which may lead to the build-up of LC3
protein in brain tissue and a subsequent accumulation of APP and
its metabolites.
Which comes first, BECN1/PIK3C3 deficiency or APP accu-
mulation? While the data from the transgenic mice suggested an
important role of Becn1 levels on AD pathology [41], it was unclear
if this effectisupstream ofAPPpathology orpartially a consequence
of disrupted intracellular trafficking due to APP overexpression.
Our cell culture data from wildtype human APP overexpressing cell
lines demonstrate now that APP overexpression alone does not lead
to reduced Becn1 and Pik3c3 levels, leaving the possibility that
autophagy disturbance could precede APP/Ab pathology in vivo,
and that the observed reduction of BECN1 in human AD brain
tissue is unlikely due to elevated levels of APP or its metabolites
alone. Instead, it suggest that an escalating disturbance in
autophagosomal flux and degradation could have a negative impact
on BECN1 and/or PIK3C3 levels, presumably via a negative
feedback loop, downregulating autophagy induction in response to
abundant autophagosome numbers (Fig. 8). Such a loop could be in
place to prevent an uncontrolled run-off activation of autophagy
with potentially disastrous consequences for the cell. In support of
such a model, pharmacological inhibition of autophagosomal-
lysosomal fusion using BafA causes a strong accumulation of
autophagosomes, accompanied with APP and APP-CTF accumu-
lationinthoseautophagosomes andotherintracellularvesicles.This
in turn leads to decreased levels of Becn1 and, at least under some
treatmentconditions,ofPik3c3(Fig.5L).Thesefindingssuggestthat
disturbances in autophagosome turnover can further inhibit proper
induction and execution of autophagy, potentially worsening the
cellular capacity to degrade APP and its metabolites.
The initial factor that impairs autophagy in AD and reduces
BECN1/PIK3C3 still has to be determined. This study however
identifies autophagy as an important degradative pathway for APP
and suggests that once autophagosomal flux and turnover is
impaired an escalating cycle of APP/APP-CTF/Ab accumulation
and further reduced initiation of autophagy occurs (Fig. 8). Future
studies of conditional knockout mice for proteins that are part of
the BECN1-PI3K complex will help to deepen our understanding
of the sequence of events that lead to the disruption of autophagy
and how this contributes to the development of AD pathology.
Materials and Methods
Cell culture
B103/hAPPwt rat neuroblastoma cells were maintained in
Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad/CA,
USA) containing 10% (v/v) fetal bovine serum and 5% (v/v) horse
serum at 37uC with 5% CO2. Selection was maintained with
400 mg/ml geneticin/G418 (Invitrogen). CHO/hAPPwt, APLP1
and APLP2 hamster ovary cells were maintained in Dulbecco’s
modified Eagle’s medium containing 10% (v/v) fetal bovine serum
andselectionmaintained using500 mg/ml hygromycin(Invitrogen).
Drug treatments/Starvation
Cells were washed once in warm PBS and covered with fresh
medium containing drugs at the indicated concentrations/for the
indicated periods: 100 nM rapamycin for 90 min (Calbiochem,
San Diego/CA, USA); 3 mM/1 mM thapsigargin for 12 hrs
(Calbiochem, San Diego/CA, USA); 50 nM/100 nM bafilomycin
A1 for 24 hrs (LC Laboratories, Woburn/MA, USA); 20 mM
ammoniumchloride and 10 mg/ml leupeptin (Sigma-Aldrich, St.
Louis/MO, USA) for 24 hrs; 30 mg/ml chloroquine (Sigma-
Aldrich, St. Louis/MO, USA) for 16 hrs; 100 nM DAPT (Sigma-
Aldrich, St. Louis/MO, USA) for 24 hrs. Control cells were
treated with the corresponding amount of vehicle. At the end of
the incubation period the cells were harvested or imaged as
described below. For starvation experiments, the cells were washed
twice in warm PBS and then incubated for 90 min in HANKS or
4 hrs in DPBS (Invitrogen, Carlsbad/CA, USA) solution.
Antibodies
The following primary antibodies were used: BECN1 antibody
#612112 1:500 (BD Biosciences, San Jose/CA, USA); LC3
antibody #PD014 1:500 WB/1:200 IHC (MBL International,
Woburn/MA, USA); PIK3C3 antibody #38-2100 1:500 (Zymed,
San Francisco/CA, USA); Actin antibody #A-5060 1:10000
(Sigma-Aldrich, St. Louis/MO, USA); Atg5 antibody 1:2000 (gift
from Dr. Noburo Mizushima, Tokyo Metropolitan Institute of
Medical Science, Japan); N-terminal APP 8E5 antibody
1:5000(WB)/1:200(IHC) (gift from Elan, South San Francisco/
CA, USA); C-terminal APP CT15/CT20 antibody 1:1000(WB)/
1:200(IHC) (gift from Dr. Todd Golde, Mayo Clinic, Jacksonville/
FL, USA); APLP1 antibody #171615 1:5000 (Calbiochem,
SanDiego/CA, USA); APLP2 antibody #171616 1:5000 (Calbio-
chem, SanDiego/CA, USA); NSE antibody #MS-171-P1 1:1000
(LabVision, Fremont/C, USA).
RNAi and LV particles
B103/hAPPwt, CHO/hAPP, CHO/hAPLP1 or CHO/hAPLP2
cells were transfected with 40 nM synthetic Stealth siRNA
(Invitrogen) using Lipofectamine 2000 (Invitrogen, Carlsbad/CA,
USA) following manufacturers instructions. The siRNA sequences
used were as follows:
BECN1: CCCAGCCAGGAUGAUGUCUACAGAA and GC-
UAACUCAGGAGAGGAGCCAUUUA.
PIK3C3: CAUUGCCGUUAGAGCCACAGGUGAA and G-
GAGCCUACCAAGAAGGAUAGUCAA.
Control: GCUACUCGAGGAGGAACCGUAAUUA.
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containing a shRNA plasmid against mBecn1 targeting the
nucleotides 405–423 (or against mAtg5) and a GFP-marker. The
control LV contained the empty plasmid with only the GFP-
marker. For the Becn1 overexpression experiments, the LV
particles contained a plasmid encoding mBecn1 alone. Cells were
transduced in 96 well plates at 50 MOI in the presence of
polybrenen (8 mg/ml). Successful transduction was monitored by
GFP expression. Following the transduction and expansion the
cells were stained or lysed after 36–96 hrs. All LV particles were
provided by Dr. E. Masliah, University of California San Diego/
CA, USA.
Protein extraction
Samples from human brain tissue were homogenized in extraction
buffer (see blow) by pulsed ultrasonification at 4uC, followed by
centrifugation at 100006ga t4 uC for 30 min. The resulting
supernatant was used for protein analysis. For cell culture samples,
cells were washed once with PBS (Invitrogen, Carlsbad/CA, USA)
and scraped off the plate. After a brief centrifugation at 45006ga t
4uC for 5 min, the cell pellets were re-suspended in extraction buffer
and homogenized by pipetting, three freeze-thaw cycles on dry ice,
and 30 min incubation on ice. Insoluble particles were pelleted by
centrifugation with 100006ga t4 uC and the resulting supernatant
was used for analysis. Proteins were extracted using RIPA buffer
(50 mM HCl, 150 mM NaCl, 5 mM EDTA, 1 mM EGTA, 20 mM
NaF,1 mMNa2VO4, 1% NP40, 0.5% Sodium deoxycholate, 1 mM
PMSF, 0.1% SDS, pH 7.4) containing 2x Complete proteinase
inhibitor (Roche Diagnostics, Mannheim, Germany). When sequen-
tial extraction was performed the samples were first extracted with
detergent free RAB buffer (MES 100 mM, EGTA 1 mM, MgSO4
0.5 mM, NaCl 750 mM, NaF 20 mM, EDTA 100 mM, Na2VO4
1 mM, PMSF 1 mM, pH 6.5) containing 2x Complete proteinase
inhibitor (Roche Diagnostics, Mannheim, Germany) followed by a
RIPA extraction of the pellet.
Western blotting
A pre-cast bis-tris gel (Invitrogen, Carlsbad/CA, USA) and a
MOPS buffer system were used and standard Western blotting
protocols were followed. 10–20 mg of total protein were loaded.
Gels were transferred onto 0.4 mm nitro-cellulose membranes
(BioRad, Hercules/CA, USA) and pre-incubated with MISER
antibody extender solution (Pierce, Rockford/IL, USA). Total
protein was measured with the BCA Protein Assay Kit (Thermo
Scientific, Rockford/IL, USA) against a BSA standard. Antigen
specific primary antibodies were incubated 1 hr at room temper-
ature or overnight at 4uC and detected with species-specific
horseradish-peroxidase coupled secondary antibodies. The ECL
Western Blotting Detection kit (GE Healthcare, Buckinghamshire,
UK) was used to obtain a chemiluminescence signal, which was
then detected using Amersham Hyperfilm ECL (GE Healthcare,
Buckinghamshire, UK) at varying exposure times to obtain images
with optimal density within the dynamic range of the film (30 s–
30 min). The films were digitalized at 300dpi and arranged in
Photoshop CS4 (Adobe, San Jose/CA, USA) as TIFF files. Band
quantification was performed using ImageJ software (NIH,
Bethesda/MD, USA). Bands of interest were normalized to a
loading control using Microsoft Excel 2008 (Microsoft Corporation,
Seattle/WA, USA) and statistical analysis and graph production
was performed in Prism5 (GraphPad Software, La Jolla/CA, USA).
Ab ELISA
ELISAs were performed as described [41] using antibody 266
(Ab13–28, Elan) as the capture antibody for total Ab, or antibody
21F12 (Ab37–42, Elan, South San Francisco/CA, USA) as the
capture antibody for Abx-42 and biotinylated 3D6 (Ab1–5, Elan,
South San Francisco/CA, USA) as the detection antibody. After
incubation with the secondary antibody, samples were incubated
with avidin-HRP and the signal developed using ‘‘1-step slow
TMB ELISA solution’’ (Thermo Scientific, Rockford/IL, USA).
For the thapsigargin-treatment experiments, we used a MesoScale
detection system (Gaithersburg/MD, USA) and followed the
standard protocol with the above antibodies.
Fluorescence Microscopy
For epifluorescence microscopy cells were grown in 12 well tissue
culture plates (Becton Dickinson Labware, Franklin Lakes/NJ,
USA). They were washed with ice-cold PBS and then fixed in cold
4% PFA in phosphate buffer for 5 min at 4uCf o l l o w e db y1 0m i na t
RT. Cells were then washed three times with ice-cold PBS and PFA
fluorescence was quenched with ice-cold 100 mM tris-HCl pH 8.0
for 3 min. The cells were then either washed three times in ice-cold
PBS and stained (forcellsurface APP)orpermeabilized with ice-cold
methanol for 6 min at 220uC, followed by three washes of ice-cold
PBS and staining (for intracellular proteins). Staining was performed
by blocking cells in blocking buffer (4% donkey serum, 2% bovine
serum albumin, 2% fetal calf serum, 0.2% fish gelatin in PBS) for
1 hr at RT. Primary antibodies in blocking buffer were applied to
the cells for 1 hr at RT, followed by three 5 min washes in PBS.
Fluorescent secondary antibodies in blocking buffer were added and
incubatedfor1 hratRT,followedbythreewashesinPBSfor5 min.
Cells were visualized with a Olympus IX71 microscope with a
CoolSnapHQ camera (Roper Scientific, Tucson/AZ, USA). Image
analysis was done with MetaMorph 6.1r6 (Molecular Devices,
Sunnyvale/CA, USA). For confocal microscopy cells were grown on
glass cover slips (Fisher Scientific, Hampton/NH, USA) in 12 well
plates, and fixed and stained similar to the epifluorescence protocol
above. The glass coverslips were mounted in MoWiol and visualized
on a Zeiss LSM 510 confocal microscope. Image analysis was done
with the Zeiss LSM software package.
RT-PCR
RNA was extracted from B103/hAPP cells (n=5 wells per
treatment group) using Trizol and cleaned using RNAeasy mini kit
(Qiagen, Valencia/CA, USA). cDNA was synthesized using
TaqMan reverse transcriptase (Applied Biosystems, Branchburg/
NJ, USA). cDNA was amplified in triplicate on a MyiQ single
color real time PCR detection system using primers specific to
human APP (F 59CACCAATGTGGTAGAAGCCAACC39,R
59GGGCAACACACAAACTCTACCCC39), and GAPDH (F
59TGCGACTTCAACAGCAACTC39,R5 9ATGTAGGCCAT-
GAGGTCCAC39). The PCR cycle was as follows: 10 min at
95uC, 45 x (30 s at 95uC, 2 min at 60uC, 30 s at 72uC). Cycle
numbers for amplification to exceed a pre-set threshold were used
to determine the APP mRNA copy number. cDNA prepared
without reverse transcriptase was amplified to ensure no genomic
DNA contamination of the samples.
Human brain tissue
Brain tissues from confirmed AD and age-matched, non-
demented, non-pathological controls were obtained from ADRC
at the University of California - San Diego, The Institute for Brain
Aging and Dementia Tissue Repository at the University of
California - Irvine, and Stanford Brain Bank at Stanford
University in strict accordance with all ethical and institutional
guidelines. Cortical mid-frontal gray matter tissue was cut out of
frozen tissue blocks and subject to protein extraction as described
above.
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Human brain tissue protein data consists of one-sample
measurements for each case. The data was normalized against
actin and differences calculated using Student’s unpaired t-test. Cell
culture western blots experiments were conducted in two to three
independent experiments consisting of duplicates or triplicates. All
measurements were normalized by actin intensities and then
calculated as levels relative to control conditions. Differences
between treatment conditions were established using student’s
unpaired t-test (with two conditions) or one-way ANOVA followed
by Dunnett’s test for multiple comparisons (for more than two
conditions). For fluorescence microscopy, stains were done in
independent duplicates and representative images chosen.
Supporting Information
Figure S1 Expression of Becn1 and Pik3c3 in the mouse brain,
especially in the hippocampus, indicates an important function of
autophagy in neuronal homeostasis (from the Allen Mouse Brain
Atlas. Seattle (WA): Allen Institute for Brain Science. Available
from http://mouse.brain-map.org).
Found at: doi:10.1371/journal.pone.0011102.s001 (0.38 MB TIF)
Figure S2 Control or Atg5 shLV treated B103/hAPP cells were
starved in DPBS for 4 hours. Atg5 and APP levels were measured
by Western-blotting and quantified. Atg5 reduction significantly
impairs starvation induced autophagosomal APP degradation
(Data is from the same blot. The vertical line indicates removal of
three lanes not part of this experiment.) Bars are mean 6 SEM
from triplicate cultures. * p,0.05, ** p,0.01, *** p,0.001 by
unpaired Student’s t test.
Found at: doi:10.1371/journal.pone.0011102.s002 (0.16 MB TIF)
Figure S3 Quantification of B103/hAPP RIPA cell lysates,
72 hours after siRNA kockdown. All bars are mean 6 SEM.
Means from at least two independent experiments were compared
by unpaired Student’s t test. * p,0.05, ** p,0.01, *** p,0.001
Found at: doi:10.1371/journal.pone.0011102.s003 (0.14 MB TIF)
Figure S4 Epifluorescence microscopy of CHO/hAPP cells treated
with Becn1 siRNA for 48 hours. All bars are mean 6 SEM. Means
from at least two independent experiments were compared by
unpaired Student’s t test. * p,0.05, ** p,0.01, *** p,0.001
Found at: doi:10.1371/journal.pone.0011102.s004 (0.85 MB TIF)
Figure S5 Western-blot of control or Becn1 shLV transduced
B103/hAPP cells that were treated with vehicle or 100 nM DAPT
for 24 hours. An anti-luciferase shLV was used as control.
Found at: doi:10.1371/journal.pone.0011102.s005 (0.30 MB TIF)
Figure S6 Western-blots and quantification of CHO/hAPP and
B103/hAPP cells treated with chloroquine (CQ) or ammoniumchlor-
ide/leupeptin (NL). Means from three independent experiments
were compared by unpaired Student’s t test. * p,0.05, ** p,0.01,
*** p,0.001
Found at: doi:10.1371/journal.pone.0011102.s006 (0.45 MB TIF)
Figure S7 A–B. Control experiments for the LV overexpression
of Becn1. Control for cell size as a measure of physiological cell
health (A). High Becn1 overexpressors exhibit either swollen or
shrunken cell bodies, indicating non-physiological stress. Quanti-
fication (B) of APP, Becn1 immunofluorescence, and cell size in
GFP LV control cells (N=100) shows no difference in APP or
Becn1 levels for low and medium overexpression of GFP. High
GFP expression induces non-physiological conditions leading to an
unspecific accumulation of Becn1 and APP and cell shrinkage.
This led us to not further explore the effects of the highest Becn1
or GFP expressing cells.
Found at: doi:10.1371/journal.pone.0011102.s007 (0.19 MB TIF)
Table S1 Human cortical gray matter tissue was subject to
sequential RAB/RIPA buffer extraction and Western blotting.
Control (N=10) and AD (N=10) cases were compared regarding
their relative BECN1, PIK3C3, and ATG5 levels. While BECN1
and PIK3C3 levels were significantly reduced in AD brains when
compared to controls, no difference was detectable in ATG5
levels.
Found at: doi:10.1371/journal.pone.0011102.s008 (0.03 MB
DOC)
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